When to Suspect Inborn Errors of Immunity in Epstein-Barr Virus-related Lymphoproliferative Disorders

Overview

Journal Clin Microbiol Infect

Publisher Elsevier

Specialty Infectious Diseases

Date 2022 Oct 9

PMID 36209991

Authors

Keith A Sacco

Luigi D Notarangelo

Ottavia M Delmonte

Affiliations

Soon will be listed here.

Abstract

Background: More than 95% of humans have been infected with Epstein-Barr virus (EBV) and develop anti-EBV IgG antibodies, conferring immunity. However, among specific populations, EBV may induce a range of B-cell lymphoproliferative disorders (LPDs). EBV may also contribute to T-cell and natural killer (NK)-cell lymphoproliferation. The immune system is essential to prevent infection and development of cancer. Inborn errors of immunity (IEIs) are a heterogenous group of more than 450 genetic disorders predisposing to severe and/or recurrent infection, autoimmunity, autoinflammation, or early-onset/severe neoplasia or lymphoproliferation. Monogenic disorders of T-cell and B-cell signalling are classic IEIs that predispose to EBV-associated LPDs.

Objectives: We aimed to outline the various clinical manifestations of EBV-associated LPDs and the underlying IEIs associated with such presentations and discuss the recommended management and therapeutic options pertaining to these disorders.

Sources: We searched PubMed, Embase, and Web of Science Core Collection on 30 September 2021. Clinical studies, systematic reviews, narrative reviews, and case reports were identified through search strategy and cross reference from primary literature.

Content: Effective T-cell and NK-cell cytotoxicity towards EBV-infected B cells relies on intact MAGT1-dependent NKG2D pathways and signalling lymphocyte activation molecular-associated protein-dependent signalling lymphocyte activation molecular receptors. The interaction between CD27 and CD70 is also critical to drive the expansion of EBV-specific T cells. IEIs due to T-cell and B-cell signalling defects and/or impaired T-cell and NK-cell cytotoxicity predispose to EBV-related lymphoproliferation. This includes classic disorders such as X-linked lymphoproliferative disease 1 (due to SH2D1A mutations), X-linked lymphoproliferative disease 2 (XIAP), and other genetic diseases, such as ITK, MAGT1, CD27, CD70, CTPS1, RASGRP1, and CORO1A deficiencies. EBV-driven lymphoproliferation may manifest to a lesser degree in MST1/STK4, DOCK8, STIM1, CORO1A, IL21R, PIK3CD gain-of-function, and PI3KR1 deficiencies.

Implications: Early screening for IEIs is indicated in cases of EBV-related lymphoproliferation because different forms of IEIs have specific prognostic and therapeutic implications.

Citing Articles

Applications of cell therapy in the treatment of virus-associated cancers.

Toner K, McCann C, Bollard C Nat Rev Clin Oncol. 2024; 21(10):709-724.

PMID: 39160243 DOI: 10.1038/s41571-024-00930-x.

Acalculous Cholecystitis as a Complication of Primary Epstein-Barr Virus Infection: A Case-Based Scoping Review of the Literature.

Tsiakalos A, Schinas G, Karatzaferis A, Rigopoulos E, Pappas C, Polyzou E Viruses. 2024; 16(3).

PMID: 38543828 PMC: 10974004. DOI: 10.3390/v16030463.

References

Locatelli F, Jordan M, Allen C, Cesaro S, Rizzari C, Rao A . Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2020; 382(19):1811-1822. DOI: 10.1056/NEJMoa1911326. View

Hoshino A, Takashima T, Yoshida K, Morimoto A, Kawahara Y, Yeh T . Dysregulation of Epstein-Barr Virus Infection in Hypomorphic ZAP70 Mutation. J Infect Dis. 2018; 218(5):825-834. DOI: 10.1093/infdis/jiy231. View

Alosaimi M, Hoenig M, Jaber F, Platt C, Jones J, Wallace J . Immunodeficiency and EBV-induced lymphoproliferation caused by 4-1BB deficiency. J Allergy Clin Immunol. 2019; 144(2):574-583.e5. PMC: 6688916. DOI: 10.1016/j.jaci.2019.03.002. View

Liu K, Bunnell S, Gurniak C, Berg L . T cell receptor-initiated calcium release is uncoupled from capacitative calcium entry in Itk-deficient T cells. J Exp Med. 1998; 187(10):1721-7. PMC: 2212298. DOI: 10.1084/jem.187.10.1721. View

Heslop H . How I treat EBV lymphoproliferation. Blood. 2009; 114(19):4002-8. PMC: 2774540. DOI: 10.1182/blood-2009-07-143545. View

Taylor G, Long H, Brooks J, Rickinson A, Hislop A . The immunology of Epstein-Barr virus-induced disease. Annu Rev Immunol. 2015; 33:787-821. DOI: 10.1146/annurev-immunol-032414-112326. View

Katzenstein A, CARRINGTON C, LIEBOW A . Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases. Cancer. 1979; 43(1):360-73. DOI: 10.1002/1097-0142(197901)43:1<360::aid-cncr2820430151>3.0.co;2-8. View

Abolhassani H, Edwards E, Ikinciogullari A, Jing H, Borte S, Buggert M . Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency. J Exp Med. 2016; 214(1):91-106. PMC: 5206499. DOI: 10.1084/jem.20160849. View

Sepulveda F, de Saint Basile G . Hemophagocytic syndrome: primary forms and predisposing conditions. Curr Opin Immunol. 2017; 49:20-26. DOI: 10.1016/j.coi.2017.08.004. View

10.

van Montfrans J, Hoepelman A, Otto S, van Gijn M, van de Corput L, de Weger R . CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia. J Allergy Clin Immunol. 2011; 129(3):787-793.e6. PMC: 3294016. DOI: 10.1016/j.jaci.2011.11.013. View

11.

Marsh R, Rao K, Satwani P, Lehmberg K, Muller I, Li D . Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. Blood. 2012; 121(6):877-83. PMC: 5162550. DOI: 10.1182/blood-2012-06-432500. View

12.

Krase I, Woodward J, Bauer C, Miller H, Sacco K . Seronegative Mediastinal Coccidioidomycosis as a Novel Presentation of CTPS1 Combined Immunodeficiency. Open Forum Infect Dis. 2022; 9(8):ofac403. PMC: 9379812. DOI: 10.1093/ofid/ofac403. View

13.

Chaigne-Delalande B, Li F, OConnor G, Lukacs M, Jiang P, Zheng L . Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science. 2013; 341(6142):186-91. PMC: 3894782. DOI: 10.1126/science.1240094. View

14.

Winter S, Martin E, Boutboul D, Lenoir C, Boudjemaa S, Petit A . Loss of RASGRP1 in humans impairs T-cell expansion leading to Epstein-Barr virus susceptibility. EMBO Mol Med. 2017; 10(2):188-199. PMC: 5801500. DOI: 10.15252/emmm.201708292. View

15.

Jacobs J, Deschoolmeester V, Zwaenepoel K, Rolfo C, Silence K, Rottey S . CD70: An emerging target in cancer immunotherapy. Pharmacol Ther. 2015; 155:1-10. DOI: 10.1016/j.pharmthera.2015.07.007. View

16.

Song J, Pittaluga S, Dunleavy K, Grant N, White T, Jiang L . Lymphomatoid granulomatosis--a single institute experience: pathologic findings and clinical correlations. Am J Surg Pathol. 2014; 39(2):141-56. PMC: 4293220. DOI: 10.1097/PAS.0000000000000328. View

17.

Nicolae A, Pittaluga S, Abdullah S, Steinberg S, Pham T, Davies-Hill T . EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood. 2015; 126(7):863-72. PMC: 4536540. DOI: 10.1182/blood-2015-02-630632. View

18.

Ok C, Papathomas T, Medeiros L, Young K . EBV-positive diffuse large B-cell lymphoma of the elderly. Blood. 2013; 122(3):328-40. PMC: 3779382. DOI: 10.1182/blood-2013-03-489708. View

19.

Marsh R, Bleesing J, Chandrakasan S, Jordan M, Davies S, Filipovich A . Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1. Biol Blood Marrow Transplant. 2014; 20(10):1641-5. DOI: 10.1016/j.bbmt.2014.06.003. View

20.

Pachlopnik Schmid J, Canioni D, Moshous D, Touzot F, Mahlaoui N, Hauck F . Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood. 2010; 117(5):1522-9. DOI: 10.1182/blood-2010-07-298372. View